Measurements of emissions for lpg combustion within a porous cylindrical burners

CO and NO[x] emission characteristics of a hollow cylindrical radiation burner operated in the external and internal combustion modes and premixed LPG+air mixtures are experimentally studies. The influence of the pore structure, equivalence ratio, firing rate and burner design are considered

ПЕРСПЕКТИВИ СТВОРЕННЯ ЕФЕКТИВНО ФУНКЦІОНУЮЧОГО ФІНАНСОВОГО МЕХАНІЗМУ ІННОВАЦІЙНОГО РОЗВИТКУ ПІДПРИЄМСТВ В УКРАЇНІ

Висвітлюються проблеми і перспективи створення ефективно функціонуючого фінансового механізму інноваційного розвитку підприємств в Україні. Розроблено модель, яка забезпечує формування стратегії інноваційного розвитку підприємства.Problems and prospects of effectively functioning financial mechanism's creation of innovative enterprise development in Ukraine are lighted. A model is developed, which provides forming of the innovative strategy enterprises' development

Clinical and Biomarker Responses to BI 655064, an Antagonistic Anti-CD40 Antibody, in Patients With Active Lupus Nephritis:A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial

Objective: To characterize its dose-response relationship, BI 655064 (an anti-CD40 monoclonal antibody) was tested as an add-on to mycophenolate and glucocorticoids in patients with active lupus nephritis (LN).Methods: A total of 121 patients were randomized (2:1:1:2) to receive placebo or BI 655064 120, 180, or 240 mg and received a weekly loading dose for 3 weeks followed by dosing every 2 weeks for the 120 and 180 mg groups, and 120 mg weekly for the 240 mg group. The primary endpoint was complete renal response (CRR) at week 52. Secondary endpoints included CRR at week 26.Results: A dose-response relationship with CRR at week 52 was not shown (BI 655064 120 mg, 38.3%; 180 mg, 45.0%; 240 mg, 44.6%; placebo, 48.3%). At week 26, 28.6% (120 mg), 50.0% (180 mg), 35.0% (240 mg), and 37.5% (placebo) achieved CRR. The unexpected high placebo response prompted a post hoc analysis evaluating confirmed CRR (cCRR, at weeks 46 and 52). cCRR was achieved in 22.5% (120 mg), 44.3% (180 mg), 38.2% (240 mg), and 29.1% (placebo) of patients. Most patients reported ≥1 adverse event (BI 655064, 85.7–95.0%; placebo, 97.5%), most frequently infections and infestations (BI 655064 61.9–75.0%; placebo 60%). Compared with other groups, higher rates of serious (20% vs. 7.5–10%) and severe infections (10% vs. 4.8–5.0%) were reported with 240 mg BI 655064.Conclusion: The trial failed to demonstrate a dose-response relationship for the primary CRR endpoint. Post hoc analyses suggest a potential benefit of BI 655064 180 mg in patients with active LN.</p